Navigation Links
EORTC study identifies patients with anaplastic oligodendroglioma that benefit from adjuvant PCV
Date:5/29/2013

A further report on the results of EORTC trial 26951 indicates that CpG island methylator phenotype (CIMP) status and O 6-methylguanine-DNA methyltransferase (MGMT) promoter methylation as assessed by MGMT-STP27 are the most informative for identifying grade III glioma patients who might benefit from the addition of procarbazine, CCNU and vincristine (PCV) chemotherapy to radiation therapy. Prior results had shown that PCV chemotherapy following standard radiation therapy delayed tumor growth and extended the lives of patients with anaplastic oligodendroglial tumors, a hard-to-treat form of brain cancer.

Results observed in the phase III RTOG 9402 trial, in this case with chemotherapy preceding radiation therapy, complemented the results obtained previously in the EORTC 26951 trial and found that administering both PCV and radiation therapy led to comparable improvements in survival for oligodendroglial tumor patients with specific deletions of genetic material in chromosomes 1p and 19q, but not for patients without the mutation.

Nevertheless up to 30% of oligodendroglial tumors do not have 1p/19q deletion but may still respond to chemotherapy. Analyses of EORTC 26951 and RTOG 9402 suggested that other molecularly defined subsets of grade III tumors might benefit as well.

The new results will be presented at an ASCO 2013 Clinical Science Symposia on Sunday, 02 June 2013 by Dr. Martin J. Van Den Bent of the Erasmus Medical Centre Cancer Institute, Rotterdam, The Netherlands, and coordinator of the study. According to Dr. Van Den Bent, "This is further evidence pointing towards a central role of methylation in the behavior of IDH (isocitrate dehydrogenase) mutated glioma and, more in general, of the MGMT gene function in glioma when treated with chemotherapy."

Methylation profiles of 115 patients were conducted using Infinium HumanMethylation27 or Infinium HumanMethylation450 BeadChip kits. (Validation in an independent data
'/>"/>

Contact: John Bean
john.bean@eortc.be
32-277-41671
European Organisation for Research and Treatment of Cancer
Source:Eurekalert

Page: 1 2

Related medicine news :

1. EORTC led intergroup trial investigates Imatinib failure-free survival in patients with GIST
2. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
3. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Now Offer New Guided Weight Loss Tips Now Found in New Study to Help Patients Lose Weight Fast
4. A Strong Marriage Can Shield Kids From Dads Depression: Study
5. Narconon Releases Early Study of Delaware Prison Program, Demonstrating Crime Reduction Consistent with More Recent Narconon Results
6. Changing gut bacteria through diet affects brain function, UCLA study shows
7. GOJO presents electronic hand hygiene compliance study at APIC conference
8. Alzheimers Patients Mimic Emotions of Those Around Them: Study
9. Study: Ipilimumab Shows Durable Responses But Low Overall Response Rate In Patients With Unresectable Or Metastatic Mucosal Melanoma
10. Kids Poisoned by Medical Marijuana, Study Finds
11. Involving Patients in Decisions Raises Health Care Costs, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... The Pearland, Texas location of The Little Gym, a gymnastics ... 12 years of age that offers everything from gymnastics, dance, ... Camps, is now under new ownership. , Kevin Berry comes ... over six years at The Little Gym of Bellaire in ... has over ten years of experience working with children, including ...
(Date:7/13/2014)... 2014 Max International has ... will be the featured guest at its Charity Exhibition ... Rico. Attendees will learn about Max’s health products ... exhibition basketball games and perform in a 3 point ... health- and energy-boosting supplements , has recently announced former ...
(Date:7/13/2014)... device developed at Cedars-Sinai can provide early detection ... and are a classic sign of Alzheimer,s disease, ... clinical trial in Australia. , The researchers will ... presentation at the Alzheimer,s Association International Conference 2014 ... conference organizers to participate in a "breaking news" ...
(Date:7/13/2014)... OH (PRWEB) July 13, 2014 A ... Wright & Schulte LLC to provide consumers with the ... sometimes accompany use of the blood-thinning medication, as well ... pending in courts around the country. The law ... who may have suffered from life-threatening internal bleeding and ...
(Date:7/13/2014)... Ann Arbor, MI (PRWEB) July 13, 2014 ... online learning program he has just launched at http://www.HealthYourself101.com ... management of visceral obesity. , Power has set out ... and its ill effects that’s actually – dare we say ... , “The program,” says Power, “aims to engage the remote ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4
... to treat injury, stroke and even Alzheimer,s, experts say , , ... study involving mice suggests the brain,s own stem cells may ... These neural stem cells work by protecting existing cells and ... the University of California, Irvine, were able to bring the ...
... As the seventh leading cause of cancer death worldwide, ... ethnic group and gender. Esophageal cancer is thought to ... interact with the host genome. Researchers have long been ... been conducted on gene-environment interaction and gene polymorphisms for ...
... remove part or all of the colon (colectomy) for people ... researchers in a study published on bmj.com today. ... of the intestine and includes ulcerative colitis and Crohns disease. ... are affected and many people will require colectomy at some ...
... MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ), ... of a Phase 2a clinical trial evaluating,MAP0005 ... chronic obstructive,pulmonary disease (COPD). MAP0005 is ... long-acting,beta2-agonist delivered to the respiratory tract using ...
... BPUR ) announced today that the trading symbol for ... BPUR at the open of the market on,Wednesday, October ... revert to the following ticker symbols: BPREW reverting to ... Biopure Corporation Biopure Corporation develops, manufactures and ...
... HRAL) announced today that it has formed an alliance ... Stores (NYSE: WMT ) to help,conquer hearing loss ... Starting November 15, 2007, HearAtLast customers will receive a,$100.00 ... with,their American Express card. The promotion is scheduled to ...
Cached Medicine News:Health News:Stem Cells Restore Memory in Mice 2Health News:Stem Cells Restore Memory in Mice 3Health News:ADH2 and ALDH2 are associated with esophageal cancer 2Health News:Threshold for bowel surgery may be too high, warn experts 2Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 2Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 3Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 4Health News:Biopure's Stock Symbol Reverts to BPUR 2Health News:HearAtLast Teams Up with American Express and Wal-Mart to Conquer Hearing Loss 2Health News:HearAtLast Teams Up with American Express and Wal-Mart to Conquer Hearing Loss 3Health News:HearAtLast Teams Up with American Express and Wal-Mart to Conquer Hearing Loss 4
(Date:7/11/2014)... , July 11, 2014 Research and ... Hypodermic Needles Market 2014-2018" report to their offering. ... A hypodermic needle is a hollow needle commonly used ... or or to extract fluids from it. A hypodermic ... to inject substances that cannot be ingested. Hypodermic needles ...
(Date:7/11/2014)... 11, 2014 Research and Markets ( ... "Immunoprotein Diagnostic Testing Market - Forecasts to ... of 6% and is expected to be valued ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... has been segmented according to immunoprotein types which ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... 6, 2012   Heska Corporation (NASDAQ: ... and other specialty veterinary products , today announced that ... practices research, tools and metrics for patent analysis and ... Heska,s Science Strength in the top 50 of the ...
...  The United States Patent & Trademark Office (USPTO) has ... ) that the USPTO has rejected all claims by ... 7,357,891 (the ,891 Patent) which is currently being asserted ... (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) ...
Cached Medicine Technology:The Patent Board Ranks Heska's Science Strength in Biotechnology Industry Top 50 2The Patent Board Ranks Heska's Science Strength in Biotechnology Industry Top 50 3US Patent Office Rejection of All Claims in Final Asserted MonoSol Patent Further Supports BioDelivery Sciences' Position 2US Patent Office Rejection of All Claims in Final Asserted MonoSol Patent Further Supports BioDelivery Sciences' Position 3
... SET LNOP Blue Sensor is the first ... The LNOP Blue sensor is the first ... for cyanotic infants and children. Cyanotic ... conditions for reliable and accurate pulse oximetry, ...
Inquire...
... The Trinity Biotech Captia™ Varicella- Zoster ... (ELISA) is intended for the detection and ... in human sera. Individual serum specimens may ... status. Paired sera, acute and convalescent, may ...
ELISA kit for Varicella-zoster IgG....
Medicine Products: